20120415-1-pub-outreach

Receptos Doses First Patient in Phase 2/3 Trial for RPC1063 in Multiple Sclerosis
The Scripps Molecular Screening Center becomes the first to have 1000 AIDs in PubChem!
Receptos Scientists Publish Determination of a High Resolution S1P1 Structure in Science
NIH Common Fund researchers uncover structure of important target for drug design
NIH Research Matters: Designing New Diabetes Drugs
Discovery of a treatable mechanism for avoiding the deadly response to flu: North County Times, Eurekalert [1, 2]
Nature: Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand
Scripps Research and MIT scientists discover class of potent anti-cancer compounds
MLP Probe Project Leads to First in Human Studies
Business Wire: Receptos Initiates Clinical Trials for S1P1 Agonist Program, Aimed at Multiple Sclerosis

Home » Publications » Outreach Publications » 20120415-1-pub-outreach

Musille PM, Pathak MC, Lauer JL, Hudson WH, Griffin PR, Ortlund EA.
Antidiabetic phospholipid-nuclear receptor complex reveals the mechanism for phospholipid-driven gene regulation.

3 Google Scholar Citations

Statistics

1,403 PubChem assays,
43,827,446 tested substances,
382,680 active substances,
72 probes
and 141 publications,
with 4155 citations

as of May 24, 2013.
More...

Funding Opportunities

Find a table of current funding opportunities here.

News Articles

Related to the Scripps Molecular Screening Center

Molecular Libraries Program News Website

Scripps News Website

Online

Navigation

Site Search

Statistics

Funding Opportunities

News Articles

Online